Science Explorer Back to mapMap
Discussion
Institution · Karus Therapeutics (United Kingdom)

Most cited papers from Karus Therapeutics (United Kingdom)

Karus Therapeutics (United Kingdom)

What are the most cited papers from Karus Therapeutics (United Kingdom)?

The most cited paper from Karus Therapeutics (United Kingdom) is "The Economic Impact of Eradicating Peste des Petits Ruminants: A Benefit-Cost Analysis" (Bryony Anne Jones, Karl M. Rich, Jeffrey C. Mariner et al., 2016), with 148 citations. Next come "Compensation between CSF1R+ macrophages and Foxp3+ Treg cells drives resistance to tumor immunotherapy" (145) and "Progress in the Preclinical Discovery and Clinical Development of Class I and Dual Class I/IV Phosphoinositide 3-Kinase (PI3K) Inhibitors" (103).

Showing 49 of 49 papers. Every paper is listed.

Most cited papers, sortable by citations and release date
#Paper
1 The Economic Impact of Eradicating Peste des Petits Ruminants: A Benefit-Cost Analysis Bryony Anne Jones, Karl M. Rich, Jeffrey C. Mariner et al. · PLoS ONE Open access 22 Feb 2016 148
2 Compensation between CSF1R+ macrophages and Foxp3+ Treg cells drives resistance to tumor immunotherapy Dávid Győri, Ee Lyn Lim, Francis M. Grant et al. · JCI Insight Open access 6 Jun 2018 145
3 Progress in the Preclinical Discovery and Clinical Development of Class I and Dual Class I/IV Phosphoinositide 3-Kinase (PI3K) Inhibitors Stephen Joseph Shuttleworth, F. A. Silva, Alexander Cecil et al. · Current Medicinal Chemistry Open access Jun 2011 103
4 IL-17E, a proinflammatory cytokine, has antitumor efficacy against several tumor types in vivo Tania Benatar, Ming Yu Cao, Yoon Lee et al. · Cancer Immunology Immunotherapy Open access 12 Dec 2009 102
5 Participatory Disease Surveillance and Response in Indonesia: Strengthening Veterinary Services and Empowering Communities to Prevent and Control Highly Pathogenic Avian Influenza Muhammad Azhar, Ade S. Lubis, Elly Sawitri Siregar et al. · Avian Diseases Mar 2010 88
6 Histone Deacetylase Inhibitors: New Promise in the Treatment of Immune and Inflammatory Diseases Stephen Joseph Shuttleworth, Sarah G. Bailey, Paul A. Townsend · Current Drug Targets Nov 2010 87
7 The First Biologically Active Synthetic Analogues of FK228, the Depsipeptide Histone Deacetylase Inhibitor Alexander Yurek‐George, Alexander Cecil, Alex Hon Kit Mo et al. · Journal of Medicinal Chemistry Open access 24 Oct 2007 84
8 Digital Games, Gender and Learning in Engineering: Do Females Benefit as Much as Males? Richard Joiner, Ioanna Iacovides, Martin R. Owen et al. · Journal of Science Education and Technology Open access 18 Dec 2010 75
9 Characterisation of the in vitro activity of the depsipeptide histone deacetylase inhibitor spiruchostatin A Simon J. Crabb, Melanie H. Howell, Helen L. Rogers et al. · Biochemical Pharmacology 21 Jun 2008 66
10 Rinderpest: The end of cattle plague P. L. Roeder · Preventive Veterinary Medicine 26 Jul 2011 65
11 Burden of Herpes Zoster in the Japanese Population with Immunocompromised/Chronic Disease Conditions: Results from a Cohort Study Claims Database from 2005–2014 Shinichi Imafuku, Taizo Matsuki, Akiko Mizukami et al. · Dermatology and Therapy Open access 19 Nov 2018 64
12 The Opportunity To Eradicate Peste des Petits Ruminants Jeffrey C. Mariner, Bryony Anne Jones, Karl M. Rich et al. · The Journal of Immunology Open access 18 Apr 2016 60
13 Multidimensional single-cell analysis identifies a role for CD2-CD58 interactions in clinical antitumor T cell responses Gabrielle Romain, Paolo Strati, Ali Rezvan et al. · Journal of Clinical Investigation Open access 26 Jul 2022 58
14 Liposome formulation of a novel hydrophobic aryl-imidazole compound for anti-cancer therapy Jubo Liu, Helen Lee, Mario Huesca et al. · Cancer Chemotherapy and Pharmacology 6 Dec 2005 49
15 Functional characterization of a novel somatic oncogenic mutation of PIK3CB Andrew D. Whale, Lucy Colman, Letitia Lensun et al. · Signal Transduction and Targeted Therapy Open access 22 Dec 2017 47
16 The Phosphoinositide 3‐Kinase Isoform PI3Kβ Regulates Osteoclast‐Mediated Bone Resorption in Humans and Mice Dávid Győri, Dániel Csete, Szilvia Benkő et al. · Arthritis & Rheumatology Open access 9 Apr 2014 30
17 Analysis of ribonucleotide reductase M2 mRNA levels in patient samples after GTI-2040 antisense drug treatment Agnes N. Juhasz, Aikaterini Vassilakos, Helen K. Chew et al. · Oncology Reports Open access May 2006 28
18 Fatty Acid Amide Hydrolase Inhibitors – Progress and Potential Ish Khanna, Christopher W. Alexander · CNS & Neurological Disorders - Drug Targets Aug 2011 27
19 A phase II study of the antisense oligonucleotide GTI-2040 plus docetaxel and prednisone as first-line treatment in castration-resistant prostate cancer Srikala S. Sridhar, Christina M. Canil, Kim N. Chi et al. · Cancer Chemotherapy and Pharmacology 2 Jul 2010 27
20 Bioenergetics breakdown in Alzheimer's disease: targets for new therapies. Uday Saxena · PubMed Open access 2011 18
21 Targeting Interleukin-1β for Pain Sivaram Pillarisetti · CNS & Neurological Disorders - Drug Targets Aug 2011 15
22 Progress in the Design and Development of Phosphoinositide 3-Kinase (PI3K) Inhibitors for the Treatment of Chronic Diseases Stephen Shuttleworth, Franck Silva, Cyrille Tomassi et al. · Progress in medicinal chemistry Book chapter 2009 13
23 Relationship Between Response and Dose in Published, Contemporary Phase I Oncology Trials Antonious Ziad Hazim, Gordon Brent Mills, Vinay K. Prasad et al. · Journal of the National Comprehensive Cancer Network Open access Apr 2020 12
24 Preclinical toxicity and toxicokinetics of GTI-2040, a phosphorothioate oligonucleotide targeting ribonucleotide reductase R2 Eckhardt S. Ferdinandi, Aikaterini Vassilakos, Yoon Lee et al. · Cancer Chemotherapy and Pharmacology 30 Sep 2010 12
25 Antitumor activity of Virulizin, a novel biological response modifier (BRM) in a panel of human pancreatic cancer and melanoma xenografts Ningping Feng, Hongnan Jin, Ming Wang et al. · Cancer Chemotherapy and Pharmacology Mar 2003 12
26 Applying a Constrained Optimization Portfolio Model to Aid Prioritization of Public Health Interventions in Malaysia Lijoy Varghese, Sharifa Ezat Wan Puteh, Nadia Schecroun et al. · Value in Health Regional Issues Open access 7 Feb 2020 11
27 Preclinical and phase I studies of KA2237, a selective and potent inhibitor of PI3K β/δ in relapsed refractory B cell lymphoma Loretta J. Nastoupil, Sattva Swarup Neelapu, Richard Eric Davis et al. · Leukemia & lymphoma/Leukemia and lymphoma 9 Aug 2021 10
28 Complete sequence, genomic organization, and chromosomal localization of the human gene encoding the SHP2-interacting transmembrane adaptor protein (SIT) Christoph Hübener, Antoaneta Mincheva, Peter Lichter et al. · Immunogenetics May 2001 10
29 Progress in the Development of Small Molecule Therapeutics Targeting Th17 Cell Function for the Treatment of Immune-Inflammatory Diseases Stephen Shuttleworth, Paul A. Townsend, Franck Silva et al. · Progress in medicinal chemistry Book chapter 2011 9
30 Pre-Clinical Evaluation of the PI3K-p110β/δ Inhibitor KA2237 in Mantle Cell Lymphoma Shengjian Huang, Loretta J. Nastoupil, Hui Guo et al. · Blood 2 Dec 2016 6
31 Racing Academy Richard Joiner, Ioanna Iacovides, Jos Darling et al. · IGI Global eBooks Book chapterOpen access 2013 6
32 From Individual Learning to Collaborative Learning— Location, Fun, and Games Martin R. Owen · IGI Global eBooks Book chapter 2009 4
33 POIESIS: a phase III study of add-on navtemadlin in JAK inhibitor-naïve myelofibrosis patients with a suboptimal response to ruxolitinib Pankit J. Vachhani, Abdulraheem Yacoub, Raajit Rampal et al. · Future Oncology Open access 7 Mar 2026 3
34 It is irrational to exclude vets from Covid‐19 control P. L. Roeder · Veterinary Record May 2020 3
35 Presence and localization of apelin and its cognate receptor in canine testes using immunohistochemical and RT-PCR techniques. Alessandro Troisi, Cecilia Dall’Aglio, Margherita Maranesi et al. · Research Square PreprintOpen access 14 Jun 2022 2
36 Randomised Controlled Trial of Intravenous Nafamostat Mesylate in COVID Pneumonitis: Phase 1b/2a Experimental Study to Investigate Safety, Pharmacokinetics and Pharmacodynamics Tom Michael Quinn et al. · SSRN Electronic Journal PreprintOpen access 2021 1
37 Lessons from Rinderpest Eradication with Reference to COVID-19 Pandemic Management Martyn H. Jeggo, P. L. Roeder · EcoHealth Open access 15 Sep 2021 1
38 Design and Development of a Novel Orally-Active, PI3K-p110Beta/Delta Inhibitor with Combined Tumor Immunotherapeutic, Growth Inhibition and Anti-Metastatic Activity Stephen Joseph Shuttleworth · Blood 3 Dec 2015 1
39 Schools in Action Mario Barajas, Sοfoklis Sotiriou, Martin R. Owen et al. · Advances in mobile and distance learning book series Book chapter 2010 1
40 Pharmacological properties of the PI3 kinase (PI3K) inhibitors PI-540 and PI-620 Florence I. Raynaud, Angela Hayes, Francesca Di Stefano et al. · Cancer Research May 2008 1
41 Wills, Living Wills and Enduring Powers of Attorney Desmond R. Laurence · Journal of the Royal College of Physicians of London Open access Nov 1995 0
42 Better Research Ethics Committees: Comments on Guidance from the Department of Health and the European Community Aubrey L. Diamond, D R Laurence · Journal of the Royal College of Physicians of London Open access Apr 1993 0
43 Felipe Samaniego Neeraj Kumar Jain, Lalit Sehgal, Richard Eric Davis et al. · Blood 2 Dec 2016 0
44 Presence and localization of apelin and its cognate receptor in the testis of the dog using immunohistochemical and molecular biology technique. Alessandro Troisi, Cecilia Dall’Aglio, Margherita Maranesi et al. · Research Square PreprintOpen access 21 Jan 2022 0
45 Pharmacokinetics of KA2237, a novel selective inhibitor of PI3K-β and PI3K-δ, in patients: A first-in-human study using PK modelling to predict drug concentrations during dose escalation James Dow, Graham P. Trevitt, Elisabeth A. Bone et al. PreprintOpen access 25 Jun 2021 0
46 92P Characterising the role of HDAC6 in the control of human macrophage IL-10 production Philip A. Beer, Elisabeth A. Bone, Hilary McElwaine-Johnn · Annals of Oncology Open access Dec 2020 0
47 A Novel Histone Deacetylase-6 Inhibitior Reveals a Potent Immunosuppressant Effect. J. Ellis, Andrew Ready, Nicholas G Inston et al. · Transplantation Jul 2014 0
48 P2‐176: Lipoxygenase mediated intracellular oxidative stress regulates Aβ42 production Uday Saxena, Venkateswarlu Akella, Kallam Anji Reddy · Alzheimer s & Dementia 25 Jun 2009 0
49 Novel synthetic analogues of the natural product histone deacetylase inhibitor FK2286289 Graham Packham, Helen L. Rogers, Fay Habens et al. · ePrints Soton (University of Southampton) Nov 2007 0

Citations are OpenAlex's own counts, from its 2026-09-23 snapshot, so the ranking can differ from Google Scholar or Web of Science. A paper is listed for an institution when any of its authors gave it as an affiliation; retracted papers and papers whose citation count cannot be traced to citing works are left out, and a preprint and the article it became are shown once. Release dates are OpenAlex's: where a source gave only a month or a year, that is what is shown. How the lists are chosen.